The CADScor®System

The CADScor® System is driving innovation in cardiac care by providing a cutting-edge, point-of-care diagnostic aid that utilizes highly sensitive acoustics and advanced computational processing to analyze the patient’s coronary blood flow. The system calculates a patient specific CAD-score, and couples it with risk factors to rapidly indicate the patient’s risk of significant coronary stenosis for immediate risk stratification, prior to potential secondary evaluation. 1
LEARN MORE ABOUT THE CADSCOR SYSTEM
3.1 Years of Zero Myocardial Infarctions (MI) in Following Low to Moderate Chest Pain
Patients 2

Can help save costs of more advanced CAD-diasnotics in up to 40% of patients 3

Non-invasive, radiation-free, rapid, easy-to-use, and clear results at the point of care

About Acarix

Acarix is a Swedish medical device company pioneering innovative solutions for early risk assessment of coronary artery disease (CAD) at the point of care. The CE-marked and FDA De Novo-cleared CADScor® System is designed for patients experiencing chest pain with suspected CAD, and helps reduce unnecessary, invasive, and costly diagnostic procedures 4. Used in more than 45,000 patients to date 5, the CADScor System combines highly sensitive acoustic detection with advanced computational analysis to assess coronary blood flow, and rule out significant CAD, with at least 96% certainty at the point of care 1. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the U.S. (ticker: ACIXF). Carnegie Investment Bank serves as the company’s Certified Advisor.
Learn more

Frequently Asked Questions

You may be able to find the information you need amongst the frequently asked questions.

go to FAQS

Contact Us!

Please enter your information in the form below to book a demo or general inquiries.

By submitting your information, you confirm you would like to be contacted by Acarix. Read our privacy notice here , if you want to know more about how we treat and protect your personal data.

Reference:  
1. User manual US-FDA v.12.Y, prevalence 10,7% 

  1. Winther S et al. Advanced heart sound analysis as a new prognostic marker in stable coronary artery disease. European Heart Journal – Digital Health (2021) 2: 279–289
  2. Bjerking LH et al. Acoustic-based rule out of stable coronary artery disease: the FILTER-SCAD trial. Eur Heart J. Published online September 1, 2024
  3. Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.
  4. Based on commercial patch use since 2017